Eli Lilly Shares Down 7.5% as Market Reacts to Slashed Q4 Forecast
Shares of Eli Lilly ( NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 billion in revenue for Q4 2024, compared to the consensus estimate of $13.97 billion.
Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
GlobalData on MSN1d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company preannounced ...
Key Takeaways Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...
Jan 13 (Reuters) - Eli Lilly (LLY.N), opens ... The new, independent company will be owned by Scorpion's current shareholders, with Lilly holding a minority equity interest. Sign up here.
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...
GlobalData on MSN2d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncologyAfter selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback